Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 852 | 2014 |
Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 574 | 2014 |
Caloric restriction mimetics enhance anticancer immunosurveillance F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ... Cancer cell 30 (1), 147-160, 2016 | 517 | 2016 |
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy J Pol, E Vacchelli, F Aranda, F Castoldi, A Eggermont, I Cremer, ... Oncoimmunology 4 (4), e1008866, 2015 | 308 | 2015 |
Trial watch: IDO inhibitors in cancer therapy E Vacchelli, F Aranda, A Eggermont, C Sautes-Fridman, E Tartour, ... Oncoimmunology 3 (10), e957994, 2014 | 247 | 2014 |
Trial Watch: Chemotherapy with immunogenic cell death inducers E Vacchelli, F Aranda, A Eggermont, J Galon, C Sautès-Fridman, I Cremer, ... Oncoimmunology 3 (3), e27878, 2014 | 181 | 2014 |
Trial Watch: Peptide vaccines in cancer therapy F Aranda, E Vacchelli, A Eggermont, J Galon, C Sautes-Fridman, ... Oncoimmunology 2 (12), e26621, 2013 | 149 | 2013 |
Trial Watch—Oncolytic viruses and cancer therapy J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ... Oncoimmunology 5 (2), e1117740, 2016 | 144 | 2016 |
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy F Aranda, E Vacchelli, A Eggermont, J Galon, WH Fridman, L Zitvogel, ... Oncoimmunology 3 (2), e27297, 2014 | 138 | 2014 |
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications A Buqué, N Bloy, F Aranda, F Castoldi, A Eggermont, I Cremer, ... Oncoimmunology 4 (4), e1008814, 2015 | 117 | 2015 |
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy E Vacchelli, F Aranda, A Eggermont, J Galon, C Sautes-Fridman, ... Oncoimmunology 3 (1), e27048, 2014 | 112 | 2014 |
Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity JM Bravo-San Pedro, V Sica, I Martins, J Pol, F Loos, MC Maiuri, ... Cell Metabolism 30 (4), 754-767. e9, 2019 | 95 | 2019 |
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer A Buqué, N Bloy, M Perez-Lanzón, K Iribarren, J Humeau, JG Pol, ... Nature Communications 11 (1), 3819, 2020 | 89 | 2020 |
Trial Watch: Toll-like receptor agonists in oncological indications F Aranda, E Vacchelli, F Obrist, A Eggermont, J Galon, C Sautès-Fridman, ... Oncoimmunology 3 (6), e29179, 2014 | 89 | 2014 |
CD6 modulates thymocyte selection and peripheral T cell homeostasis M Orta-Mascaró, M Consuegra-Fernández, E Carreras, R Roncagalli, ... Journal of experimental medicine 213 (8), 1387-1397, 2016 | 88 | 2016 |
Trial watch: dendritic cell-based anticancer therapy N Bloy, J Pol, F Aranda, A Eggermont, I Cremer, WH Fridman, J Fučíková, ... Oncoimmunology 3 (11), e963424, 2014 | 84 | 2014 |
Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression N Díaz-Valdés, M Basagoiti, J Dotor, F Aranda, I Monreal, JI Riezu-Boj, ... Cancer research 71 (3), 812-821, 2011 | 84 | 2011 |
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer F Aranda, N Bloy, J Pesquet, B Petit, K Chaba, A Sauvat, O Kepp, ... Oncogene 34 (23), 3053-3062, 2015 | 83 | 2015 |
Trial Watch: Immunotherapy plus radiation therapy for oncological indications E Vacchelli, N Bloy, F Aranda, A Buqué, I Cremer, S Demaria, ... Oncoimmunology 5 (9), e1214790, 2016 | 81 | 2016 |
Peptide inhibitors of transforming growth factor‐β enhance the efficacy of antitumor immunotherapy D Llopiz, J Dotor, N Casares, J Bezunartea, N Díaz‐Valdés, M Ruiz, ... International Journal of Cancer 125 (11), 2614-2623, 2009 | 80 | 2009 |